A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT. jmsi [Internet]. 2026 Mar. 19 [cited 2026 Mar. 20];5(03):1550-3. Available from: https://ijmri.de/index.php/jmsi/article/view/6541